Zhitong Finance App News, Jianshi Technology-B (09877.HK) announced that Lux-Valve Plus, a transcatheter tricuspid valve replacement system independently developed by the company, recently successfully completed the implantation of the first batch of subjects in key registered clinical trials (Pivotal Trials) approved by the US Food and Drug Administration (FDA), and breakthrough progress has been made in US registered clinical trials. This marks another important milestone in the Group's globalization strategy after the product obtained EU MDR CE certification.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.